1 Ocak 2023 Dergi makalesi Açık Erişim

Senol, Halil; Ozgun-Acar, Ozden; Dag, Aydan; Eken, Ahmet; Guner, Huseyin; Aykut, Zaliha Gamze; Topcu, Gulacti; Sen, Alaattin

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Senol, Halil</dc:creator>
  <dc:creator>Ozgun-Acar, Ozden</dc:creator>
  <dc:creator>Dag, Aydan</dc:creator>
  <dc:creator>Eken, Ahmet</dc:creator>
  <dc:creator>Guner, Huseyin</dc:creator>
  <dc:creator>Aykut, Zaliha Gamze</dc:creator>
  <dc:creator>Topcu, Gulacti</dc:creator>
  <dc:creator>Sen, Alaattin</dc:creator>
  <dc:date>2023-01-01</dc:date>
  <dc:description>Multiple sclerosis (MS) treatment has received much attention, yet there is still no certain cure. We herein investigate the therapeutic effect of olean-12-en-28-ol, 3 beta- pentacosanoate (OPCA) on a preclinical model of MS. First, OPCA was synthesized semisynthetically and characterized. Then, the mice with MOG35-55-induced experimental autoimmune/ allergic encephalomyelitis (EAE) were given OPCA along with a reference drug (FTY720). Biochemical, cellular, and molecular analyses were performed in serum and brain tissues to measure anti-inflammatory and neuroprotective responses. OPCA treat-ment protected EAE-induced changes in mouse brains maintaining blood-brain barrier integrity and preventing inflammation. Moreover, the protein and mRNA levels of MS-related genes such as HLD-DR1, CCL5, TNF-alpha, IL6, and TGFB1 were significantly reduced in OPCA-treated mouse brains. Notably, the expression of genes, including PLP, MBP, and MAG, involved in the development and structure of myelin was significantly elevated in OPCA-treated EAE. Furthermore, therapeutic OPCA effects included a substantial reduction in pro-inflammatory cytokines in the serum of treated EAE animals. Lastly, following OPCA treatment, the promoter regions for most inflammatory regulators were hypermethylated. These data support that OPCA is a valuable and appealing candidate for human MS treatment since OPCA not only normalizes the pro-and anti-inflammatory immunological bias but also stimulates remyelination in EAE.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/273276</dc:identifier>
  <dc:identifier>oai:aperta.ulakbim.gov.tr:273276</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>JOURNAL OF NATURAL PRODUCTS 86(1) 16</dc:source>
  <dc:title>Synthesis and Comprehensive in Vivo Activity Profiling of Olean-12-en-28-ol, 3β-Pentacosanoate in Experimental Autoimmune Encephalomyelitis: A Natural Remyelinating and Anti-Inflammatory Agent</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>